Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

J Erin Wiedmeier-Nutor, Surendra Dasari, Richard Kumaran Kandasamy, Kiran Manalaparthi, Laura Ann Bruins, Gregory Ahmann, Mariano Arribas, P. Leif Bergsagel, Akhilesh Pandey, Esteban Braggio, Rafael Fonseca

Blood (2024) 144 (Supplement 1): 3269.

https://doi.org/10.1182/blood-2024-206239

Published: 2024

Journal Articles

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Yuan Xiao Zhu, Gregory J Ahmann, Laura Ann Bruins, Mariano Arribas, Xianfeng Chen, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca, Lisa M. Rimsza

Blood (2022) 140 (Supplement 1): 4187–4188.

https://doi.org/10.1182/blood-2022-157316

Published: 2022

Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio

Blood (2022) 140 (Supplement 1): 4135–4136.

https://doi.org/10.1182/blood-2022-170944

Published: 2022

Journal Articles

Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM)

Yuan Xiao Zhu, Laura Ann Bruins, Joseph Ahmann, Cecilia Bonolo De Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Gregory J Ahmann, Rafael Fonseca

Blood (2021) 138 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2021-153747

Published: 2021

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Laura Ann Bruins, BS, Cecilia Bonolo De Campos, PhD, William Stewart, Esteban Braggio, PhD, A Keith Stewart, M.B. Ch.B.

Blood (2019) 134 (Supplement_1): 4337.

https://doi.org/10.1182/blood-2019-127149

Published: 2019

Journal Articles

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Xuewei Wang, PhD, Daniel Riggs, PhD, Brooke Porter, Jonathan Ahmann, BS, Esteban Braggio, PhD, P. Leif Bergsagel, MD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4369.

https://doi.org/10.1182/blood.V130.Suppl_1.4369.4369

Published: 2017

Journal Articles

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria Wang, Laura Ann Bruins, BS, Santiago Barrio, PhD, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Mark R. Litzow, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D Shanafelt, MD

Blood (2017) 130 (Supplement 1): 4288.

https://doi.org/10.1182/blood.V130.Suppl_1.4288.4288

Published: 2017

Journal Articles

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Meaghen E Sharik, BS, Caleb K Stein, MS, Gregory J Ahmann, BS, Ilsel D Lopez Armenta, BS, Nikolai Sepetov, PhD, Sergei Romanov, PhD, P. Leif Bergsagel, MD, Marta Chesi, PhD, Nathalie Meurice, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 4423.

https://doi.org/10.1182/blood.V130.Suppl_1.4423.4423

Published: 2017

Journal Articles

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Nathalie Meurice, PhD, Joachim L Petit, PhD, Cecilia Bonolo De Campos, PhD, Alysia N Polito, BS, Ilsel D Lopez Armenta, BS, Gregory J Ahmann, BS, Laura Ann Bruins, BS, Joseph R Mikhael, MD FRCPC, MD, Craig B. Reeder, MD, Angela A Mayo, MS, PA-C, P. Leif Bergsagel, MD, Rafael Fonseca, MD, Nikolai Sepetov, PhD, Sergei Romanov, PhD, A. Keith Stewart, MBChB, MBA

Blood (2017) 130 (Supplement 1): 3080.

https://doi.org/10.1182/blood.V130.Suppl_1.3080.3080

Published: 2017

Journal Articles

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Esteban Braggio, PhD, Victoria X Wang, Santiago Garcia, PhD, Laura Ann Bruins, Connie Lesnick, Jacqueline C. Barrientos, MD, Susan M. O'Brien, MD, Martin S. Tallman, MD, Rafael Fonseca, MD, Neil E. Kay, MD, Tait D. Shanafelt, MD

Blood (2016) 128 (22): 4373.

https://doi.org/10.1182/blood.V128.22.4373.4373

Published: 2016

Journal Articles

Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Chang-Xin Shi, PhD, Klaus M Kortum, MD, Yuan Xiao Zhu, PhD, Patrick Jedlowski, Esteban Braggio, PhD, Laura Ann Bruins, Patrick G. Votruba, M.S., Moulun Luo, PhD, Robert A. Stewart, Jonathan M. Ahmann, A. Keith Stewart

Blood (2015) 126 (23): 450.

https://doi.org/10.1182/blood.V126.23.450.450

Published: 2015

Journal Articles

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Blood (2015) 126 (23): 723.

https://doi.org/10.1182/blood.V126.23.723.723

Published: 2015

Journal Articles

Identification of FAM46C As a Multiple Myeloma Repressor

Yuan Xiao Zhu, PhD, Chang-Xin Shi, PhD, Patrick Jedlowski, Klaus Martin Kortum, Laura Ann Bruins, Jonathan Ahmann, Esteban Braggio, PhD, Xuewei Wang, A. Keith Stewart

Blood (2015) 126 (23): 836.

https://doi.org/10.1182/blood.V126.23.836.836

Published: 2015

Journal Articles

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

Blood (2015) 126 (23): 1795.

https://doi.org/10.1182/blood.V126.23.1795.1795

Published: 2015

Journal Articles

Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing

K. Martin Kortuem, MD, A. Keith Stewart, MD, Laura Ann Bruins, Gregory Ahmann, BS, George Vasmatzis, PhD, S. Vincent Rajkumar, MD, Shaji Kumar, MD, Angela Dispenzieri, MD, Martha Q Lacy, MD, Morie A Gertz, MD, Rafael Fonseca, MD, Mia Champion, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD

Blood (2014) 124 (21): 169.

https://doi.org/10.1182/blood.V124.21.169.169

Published: 2014

NARROW

A Proteogenomic Approach to Identify Potential Drivers of Hyperdiploid Multiple Myeloma

Newly Diagnosed, Untreated, Multiple Myeloma (MM) Patient Samples Already Harbor Cereblon (CRBN) Exon 10 Deletions Associated with Drug Resistance

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Identifying Mechanisms Associated with Venetoclax Resistance in Multiple Myeloma (MM)

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Lenalidomide, Pomalidomide and CC-220 Resistant Multiple Myeloma: Confirmation of Role of CRBN/IRF4 Axis and Identification of Multiple Disruption Mechanisms

Targeted Deep Sequencing in Untreated Progressive CLL Helps to Better Dissect the Genomic Landscape and Shows Novel Associations between Mutations, Prognostic and Clinical Parameters: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

PIKfyve Inhibitors for the Treatment of Multiple Myeloma

"Direct to Drug" Screening As a Route to Individualized Therapy in Multiple Myeloma

Novel Associations Between Mutations, Prognostic and Clinical Parameters in Untreated Progressive CLL: Data from E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Crispr Sgrnas Genome-Wide Screen Identifies the Proteasome Regulatory Subunit PSMC6 As a Bortezomib Resistance Gene in Human Multiple Myeloma Cells

Targeted Sequencing of Relapsed/Refractory Myeloma Patients Identifies an Enrichment of Mutations in Cereblon and MAPK Pathways

Identification of FAM46C As a Multiple Myeloma Repressor

Targeted Genomic Mutation Panel (M 3 P) Results from 504 Multiple Myeloma (MM) Patients

Development and Results of a Multiple Myeloma Specific Custom 77-Gene Mutation Panel for Clinical Targeted Sequencing

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only